

CLAIMS

What is claimed is:

1. A method of inhibiting the ability of a cell to degrade an extracellular matrix, the method comprising inhibiting the activity of 22437 protein expressed by the cell, whereby
5 the ability of the cell to degrade the extracellular matrix is inhibited.
2. The method of claim 1, wherein the activity of 22437 protein expressed by the cell is inhibited by inhibiting expression of the 22437 gene in the cell.
- 10 3. The method of claim 2, wherein expression of the 22437 gene is inhibited by administering to the cell an antisense oligonucleotide which hybridizes under stringent conditions with a transcript of the 22437 gene.
- 15 4. The method of claim 3, wherein the antisense oligonucleotide comprises at least 15 nucleotide residues.
5. The method of claim 3, wherein the transcript is an mRNA.
- 20 6. The method of claim 2, wherein expression of the 22437 gene is inhibited by administering to the cell an antisense oligonucleotide which hybridizes under stringent conditions with a polynucleotide having the nucleotide sequence SEQ ID NO: 1.
- 25 7. The method of claim 2, wherein expression of the 22437 gene is inhibited by administering to the cell an antisense oligonucleotide which hybridizes under stringent conditions with a polynucleotide having the nucleotide sequence SEQ ID NO: 3.
8. The method of claim 1, wherein the activity of 22437 protein expressed by the cell is inhibited by inhibiting a catalytic activity of 22437 protein without significantly affecting 22437 gene expression in the cell.

30

9. The method of claim 1, wherein the activity of 22437 is inhibited by administering to the cell an agent which inhibits an activity of 22437 protein.

10. The method of claim 9, wherein the agent is an antibody which specifically
5 binds with 22437 protein.

11. The method of claim 9, wherein the activity is sulfatase activity.

12. The method of claim 9, wherein the activity is ability to degrade an
10 extracellular matrix.

13. The method of claim 1, wherein the cell is a tumor cell.

14. The method of claim 13, wherein the tumor cell is selected from the group
15 consisting of a colon tumor cell, an ovarian cancer cell, a breast cancer cell, a lung cancer cell,
and a glioblastoma cell.

15. The method of claim 1, wherein the cell is a vascular endothelial cell.

16. The method of claim 1, wherein the cell is a neuronal cell.
20

17. The method of claim 16, wherein the neuronal cell is selected from the
group consisting of an astrocyte, a neuron of the cerebral cortex, and a neuron of the
hypothalamus.
25

18. The method of claim 1, wherein the cell is in the body of a human.

19. A method for assessing whether a test compound is useful for modulating at
least one phenomenon selected from the group consisting of tumor establishment, tumor

growth, tumor metastasis, epithelial cell proliferation, endothelial cell proliferation, neuronal cell growth, wound healing, and cerebral injury healing, the method comprising:

a) adding the test compound to a first composition comprising a polypeptide that has an amino acid sequence at least 80% identical to SEQ ID NO: 2 and that exhibits a 22437 activity

5 and;

b) comparing the 22437 activity in the first composition and 22437 activity in a second composition that is substantially identical to the first, except that it does not comprise the test compound,

whereby a difference in 22437 activity in the first and second compositions is an indication that
10 the test compound is useful for modulating the phenomenon.

20. The method of claim 19, wherein the activity is selected from the group consisting of sulfatase activity and ability to degrade an extracellular matrix.

21. The method of claim 19, wherein the protein has the amino acid sequence
15 SEQ ID NO: 2.

22. The method of claim 19, wherein the first composition comprises a cell comprising a nucleic acid encoding the protein.
20

23. The method of claim 22, wherein the nucleic acid is the genome of the cell.

24. The method of claim 22, wherein the nucleic acid comprises the 22437 gene

25. A method for assessing whether a test compound is useful for modulating at
25 least one phenomenon selected from the group consisting of tumor establishment, tumor growth, tumor metastasis, epithelial cell proliferation, endothelial cell proliferation, neuronal cell growth, wound healing, and cerebral injury healing, the method comprising:

a) adding the test compound to a first composition comprising a cell which comprises a nucleic acid that encodes a polypeptide that has an amino acid sequence at least 80% identical to SEQ ID NO: 2 and that exhibits a 22437 activity and;

5 b) comparing 22437 activity in the first composition and 22437 activity in a second composition that is substantially identical to the first composition, except that it does not comprise the test compound, whereby a difference in 22437 activity in the first and second compositions is an indication that the test compound is useful for modulating the phenomenon.

10 26. A method of making a pharmaceutical composition for modulating at least one phenomenon selected from the group consisting of tumor establishment, tumor growth, tumor metastasis, epithelial cell proliferation, endothelial cell proliferation, neuronal cell growth, wound healing, and cerebral injury healing, the method comprising:

15 a) selecting a test compound useful for modulating the phenomenon according to the method of claim 19; and

b) combining the test compound with a pharmaceutically acceptable carrier in order to make the pharmaceutical composition.

20 27. A method of modulating, in a human, at least one phenomenon selected from the group consisting of tumor establishment, tumor growth, tumor metastasis, epithelial cell proliferation, endothelial cell proliferation, neuronal cell growth, wound healing, and cerebral injury healing, the method comprising administering the pharmaceutical composition of claim 26 to the human in an amount effective to modulate the phenomenon.

25 28. A method for identifying a compound useful for modulating at least one phenomenon selected from the group consisting of tumor establishment, tumor growth, tumor metastasis, epithelial cell proliferation, endothelial cell proliferation, neuronal cell growth, wound healing, and cerebral injury healing, the method comprising:

30 a) contacting the test compound and a polypeptide selected from the group consisting of

i) a polypeptide which is encoded by a nucleic acid molecule comprising a portion having a nucleotide sequence which is at least 60% identical to either of SEQ ID NOs: 1 and 3; and

5 ii) a fragment of a polypeptide having either an amino acid sequence comprising SEQ ID NO: 2, wherein the fragment comprises at least 15 contiguous amino acid residues of SEQ ID NO: 2

or a cell that expresses the polypeptide; and

b) determining whether the polypeptide binds with the test compound, whereby binding of the polypeptide and the test compound is an indication that the test
10 compound is useful for modulating the phenomenon.

29. The method of claim 28, wherein the polypeptide exhibits an activity selected from the group consisting of sulfatase activity and ability to degrade an extracellular matrix.

15 30. The method of claim 28, wherein the polypeptide exhibits an epitope in common with a polypeptide having the amino acid sequence SEQ ID NO: 2.

SEQUENCE LISTING

<110> GLUCKSMANN, Maria A.

MEYERS, Rachel

KAPELLER-LIBERMANN, Rosana

SILOS-SANTIAGO, Inmaculada

<120> 22437, A NOVEL HUMAN SULFATASE AND USES THEREFOR

<130> 10147-61U1

<140> NOT YET ASSIGNED

<141> 2001-10-03

<150> US 60/257,082

<151> 2000-12-21.

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 3513

<212> DNA

<213> Homo sapiens

<400> 1

```

cgcgctccggg cagattcacg tcgtttccag ccaagtggac ctgatcgatg gccctcctga 60
atttatcacg atatttgatt tattagcgat gcccctggt ttgtgtgtta cgcacacaca 120
cgtgcacaca aggctctggc tcgcttcctt ccctcgtttc cagctcctgg gcgaatccca 180
catctgtttc aactctccgc cgagggcgag caggagcgag agtgtgtcga atctgcgagt 240
gaagagggac gagggaaaag aaacaaagcc acagacgcaa cttgagactc ccgcatccca 300
aaagaagcac cagatcagca aaaaaagaag atgggcccc cgagcctcgt gctgtgcttg 360
ctgtccgcaa ctgtgttctc cctgctgggt ggaagctcgg ccttcctgtc gcaccaccgc 420
ctgaaaggca ggtttcagag ggaccgcagg aacatccgcc ccaacatcat cctggtgctg 480
acggacgacc aggatgtgga gctgggttcc atgcaggtga tgaacaagac ccggcgcatc 540
atggagcagg gcgggacgca cttcatcaac gccttcgtga ccacacccat gtgctgcccc 600
tcacgctcct ccctcctcac cggcaagtac gtccacaacc acaacaccta caccaacaat 660
gagaactgct cctcgccctc ctggcaggca cagcacgaga gccgcacctt tgccgtgtac 720
ctcaatagca ctggctaccg gacagctttc ttcgggaagt atcttaatga atacaacggc 780
tcctacgtgc caccgggtg gaaggagtgg gtccgactcc ttaaaaactc ccgcttttat 840
aactacacgc tgtgtcggaa cggggtgaaa gagaagcacg gctccgacta ctccaaggat 900
tacctcacag acctcatcac caatgacagc gtgagcttct tccgcacgtc caagaagatg 960
taccgcgaca ggccagtcct catggtcatc agccatgcag ccccccacgg cctgaggat 1020
tcagccccac aatattcacg cctcttccca aacgcattct agcacatcac gccgagctac 1080
aactacgcgc ccaaccggga caaactctgg atcatgcgct acacggggcc catgaagccc 1140
atccacatgg aattcaccaa catgctccag cggaagcgct tgcagaccct catgtcgggtg 1200
gacgactcca tggagacgat ttacaacatg ctggttgaga cgggcgagct ggacaacacg 1260

```

tacatcgtat	acaccgccga	ccacggttac	cacatcggcc	agtttggcct	ggtgaaaggg	1320
aaatccatgc	catatgagtt	tgacatcagg	gtcccgttct	acgtgagggg	ccccaacgtg	1380
gaagccggct	gtctgaatcc	ccacatcgtc	ctcaacattg	acctggcccc	caccatcctg	1440
gacattgcag	gcctggacat	acctgcggat	atggacggga	aatccatcct	caagctgctg	1500
gacacggagc	ggccggtgaa	tcggtttcac	ttgaaaaaga	agatgagggg	ctggcgggac	1560
tccttcttgg	tggagagagg	caagctgcta	cacaagagag	acaatgacaa	ggtggacgcc	1620
caggaggaga	actttctgcc	caagtaccag	cgtgtgaagg	acctgtgtca	gcgtgctgag	1680
taccagacgg	cgtgtgagca	gctgggacag	aagtggcagt	gtgtggagga	cgccacgggg	1740
aagctgaagc	tgcataagtg	caagggcccc	atgcggctgg	gcggcagcag	agccctctcc	1800
aacctcgtgc	ccaagtacta	cgggcagggc	agcgaggcct	gcacctgtga	cagcggggac	1860
tacaagctca	gcctggccgg	acgccggaaa	aaactcttca	agaagaagta	caaggccagc	1920
tatgtccgca	gtcgtcccat	ccgctcagtg	gccatcgagg	tggacggcag	ggtgtaccac	1980
gtaggcctgg	gtgatgccgc	ccagccccga	aacctcacca	agcggcactg	gccagggggc	2040
cctgaggacc	aagatgacaa	ggatggtggg	gacttcagtg	gcactggagg	ccttccccgac	2100
tactcagccg	ccaaccccat	taaagtgaca	catcgggtgt	acatcctaga	gaacgacaca	2160
gtccagtgtg	acctggacct	gtacaagtc	ctgcaggcct	ggaaagacca	caagctgcac	2220
atcgaccacg	agattgaaac	cctgcagaac	aaaattaaga	acctgagggg	agtccgaggt	2280
cacctgaaga	aaaagcggcc	agaagaatgt	gactgtcaca	aaatcagcta	ccacaccag	2340
cacaaaaggcc	gcctcaagca	cagaggctcc	agtctgcctc	ctttcaggaa	gggcctgcaa	2400
gagaaggaca	aggtgtggct	gttgcgggag	cagaagcgca	agaagaaact	ccgcaagctg	2460
ctcaagcgcc	tgcagaacaa	cgacacgtgc	agcatgccag	gcctcacgtg	cttcacccac	2520
gacaaccagc	actggcagac	ggcgcttttc	tggacactgg	ggcctttctg	tgctgcacc	2580
agcgccaaca	ataacacgta	ctggtgcatg	aggaccatca	atgagactca	caatttctct	2640
ttctgtgaat	ttgcaactgg	cttcctagag	tactttgato	tcaacacaga	cccctaccag	2700
ctgatgaatg	cagtgaacac	actggacagg	gatgtcctca	accagctaca	cgtacagctc	2760
atggagctga	ggagctgcaa	gggttacaag	cagtgttaacc	cccggactcg	aaacatggac	2820
ctgggactta	aagatggagg	aagctatgag	caatacaggc	agtttcagcg	tcgaaagtgg	2880
ccagaaatga	agagaccttc	ttccaaatca	ctgggacaac	tgtgggaagg	ctgggaaggt	2940
taagaaacaa	cagagtgga	cctccaaaaa	catagaggca	tcacctgact	gcacaggcaa	3000
tgaaaaacca	tgtgggtgat	ttccagcaga	cctgtgctat	tggccaggag	gcctgagaaa	3060
gcaagcacgc	actctcagtc	aacatgacag	attctggagg	ataaccagca	ggagcagaga	3120
taacttcagg	aagtccatth	ttgcccctgc	ttttgctttg	gattatacct	caccagctgc	3180
acaaaatgca	ttttttcgta	tcaaaaagtc	accactaacc	ctcccccgaga	agctcacaaa	3240
ggaaaacgga	gagagcgagc	gagagagatt	tccttggaag	tttctcccaa	gggcgaaagt	3300
cattggaatt	tttaaactcat	aggggaaaag	cagtcctgtt	ctaaatcctc	ttattctttt	3360
ggtttgtcac	aaagaaggaa	ctaagaagca	ggacagaggc	aacgtggaga	ggctgaaaac	3420
agtgcagaga	cgtttgacaa	tgagtcagta	gcacaaaaga	gatgacattt	acctagcact	3480
ataaacctcg	gttgctctcg	aagaaactgc	ctt			3513

<210> 2

Ser Leu Leu Gly Gly Ser Ser Ala Phe Leu Ser His His Arg Leu Lys
 20 25 30

Gly Arg Phe Gln Arg Asp Arg Arg Asn Ile Arg Pro Asn Ile Ile Leu
 35 40 45

Val Leu Thr Asp Asp Gln Asp Val Glu Leu Gly Ser Met Gln Val Met
 50 55 60

Asn Lys Thr Arg Arg Ile Met Glu Gln Gly Gly Thr His Phe Ile Asn
 65 70 75 80

Ala Phe Val Thr Thr Pro Met Cys Cys Pro Ser Arg Ser Ser Ile Leu
 85 90 95

Thr Gly Lys Tyr Val His Asn His Asn Thr Tyr Thr Asn Asn Glu Asn
 100 105 110

Cys Ser Ser Pro Ser Trp Gln Ala Gln His Glu Ser Arg Thr Phe Ala
 115 120 125

Val Tyr Leu Asn Ser Thr Gly Tyr Arg Thr Ala Phe Phe Gly Lys Tyr
 130 135 140

Leu Asn Glu Tyr Asn Gly Ser Tyr Val Pro Pro Gly Trp Lys Glu Trp
 145 150 155 160

Val Gly Leu Leu Lys Asn Ser Arg Phe Tyr Asn Tyr Thr Leu Cys Arg
 165 170 175

Asn Gly Val Lys Glu Lys His Gly Ser Asp Tyr Ser Lys Asp Tyr Leu
 180 185 190

Thr Asp Leu Ile Thr Asn Asp Ser Val Ser Phe Phe Arg Thr Ser Lys
 195 200 205

Lys Met Tyr Pro His Arg Pro Val Leu Met Val Ile Ser His Ala Ala
 210 215 220

Pro His Gly Pro Glu Asp Ser Ala Pro Gln Tyr Ser Arg Leu Phe Pro
 225 230 235 240

Asn Ala Ser Gln His Ile Thr Pro Ser Tyr Asn Tyr Ala Pro Asn Pro
 245 250 255

Asp Lys His Trp Ile Met Arg Tyr Thr Gly Pro Met Lys Pro Ile His
 260 265 270

Met Glu Phe Thr Asn Met Leu Gln Arg Lys Arg Leu Gln Thr Leu Met
275 280 285

Ser Val Asp Asp Ser Met Glu Thr Ile Tyr Asn Met Leu Val Glu Thr
290 295 300

Gly Glu Leu Asp Asn Thr Tyr Ile Val Tyr Thr Ala Asp His Gly Tyr
305 310 315 320

His Ile Gly Gln Phe Gly Leu Val Lys Gly Lys Ser Met Pro Tyr Glu
325 330 335

Phe Asp Ile Arg Val Pro Phe Tyr Val Arg Gly Pro Asn Val Glu Ala
340 345 350

Gly Cys Leu Asn Pro His Ile Val Leu Asn Ile Asp Leu Ala Pro Thr
355 360 365

Ile Leu Asp Ile Ala Gly Leu Asp Ile Pro Ala Asp Met Asp Gly Lys
370 375 380

Ser Ile Leu Lys Leu Leu Asp Thr Glu Arg Pro Val Asn Arg Phe His
385 390 395 400

Leu Lys Lys Lys Met Arg Val Trp Arg Asp Ser Phe Leu Val Glu Arg
405 410 415

Gly Lys Leu Leu His Lys Arg Asp Asn Asp Lys Val Asp Ala Gln Glu
420 425 430

Glu Asn Phe Leu Pro Lys Tyr Gln Arg Val Lys Asp Leu Cys Gln Arg
435 440 445

Ala Glu Tyr Gln Thr Ala Cys Glu Gln Leu Gly Gln Lys Trp Gln Cys
450 455 460

Val Glu Asp Ala Thr Gly Lys Leu Lys Leu His Lys Cys Lys Gly Pro
465 470 475 480

Met Arg Leu Gly Gly Ser Arg Ala Leu Ser Asn Leu Val Pro Lys Tyr
485 490 495

Tyr Gly Gln Gly Ser Glu Ala Cys Thr Cys Asp Ser Gly Asp Tyr Lys
500 505 510

Leu Ser Leu Ala Gly Arg Arg Lys Lys Leu Phe Lys Lys Lys Tyr Lys
515 520 525

Ala Ser Tyr Val Arg Ser Arg Ser Ile Arg Ser Val Ala Ile Glu Val
530 535 540

Asp Gly Arg Val Tyr His Val Gly Leu Gly Asp Ala Ala Gln Pro Arg
545 550 555 560

Asn Leu Thr Lys Arg His Trp Pro Gly Ala Pro Glu Asp Gln Asp Asp
565 570 575

Lys Asp Gly Gly Asp Phe Ser Gly Thr Gly Gly Leu Pro Asp Tyr Ser
580 585 590

Ala Ala Asn Pro Ile Lys Val Thr His Arg Cys Tyr Ile Leu Glu Asn
595 600 605

Asp Thr Val Gln Cys Asp Leu Asp Leu Tyr Lys Ser Leu Gln Ala Trp
610 615 620

Lys Asp His Lys Leu His Ile Asp His Glu Ile Glu Thr Leu Gln Asn
625 630 635 640

Lys Ile Lys Asn Leu Arg Glu Val Arg Gly His Leu Lys Lys Lys Arg
645 650 655

Pro Glu Glu Cys Asp Cys His Lys Ile Ser Tyr His Thr Gln His Lys
660 665 670

Gly Arg Leu Lys His Arg Gly Ser Ser Leu His Pro Phe Arg Lys Gly
675 680 685

Leu Gln Glu Lys Asp Lys Val Trp Leu Leu Arg Glu Gln Lys Arg Lys
690 695 700

Lys Lys Leu Arg Lys Leu Leu Lys Arg Leu Gln Asn Asn Asp Thr Cys
705 710 715 720

Ser Met Pro Gly Leu Thr Cys Phe Thr His Asp Asn Gln His Trp Gln
725 730 735

Thr Ala Pro Phe Trp Thr Leu Gly Pro Phe Cys Ala Cys Thr Ser Ala
740 745 750

Asn Asn Asn Thr Tyr Trp Cys Met Arg Thr Ile Asn Glu Thr His Asn
755 760 765

Phe Leu Phe Cys Glu Phe Ala Thr Gly Phe Leu Glu Tyr Phe Asp Leu
770 775 780

Asn Thr Asp Pro Tyr Gln Leu Met Asn Ala Val Asn Thr Leu Asp Arg
785 790 795 800

Asp Val Leu Asn Gln Leu His Val Gln Leu Met Glu Leu Arg Ser Cys
805 810 815

Lys Gly Tyr Lys Gln Cys Asn Pro Arg Thr Arg Asn Met Asp Leu Gly
820 825 830

Leu Lys Asp Gly Gly Ser Tyr Glu Gln Tyr Arg Gln Phe Gln Arg Arg
835 840 845

Lys Trp Pro Glu Met Lys Arg Pro Ser Ser Lys Ser Leu Gly Gln Leu
850 855 860

Trp Glu Gly Trp Glu Gly
865 870

<210> 3

<211> 2610

<212> DNA

<213> Homo sapiens

<400> 3

atgggcccc cgagcctcgt gctgtgcttg ctgtccgcaa ctgtgttctc cctgctgggt 60
ggaagctcgg ccttcctgtc gcaccaccgc ctgaaaggca ggtttcagag ggaccgcagg 120
aacatccgcc ccaacatcat cctggtgctg acggacgacc aggatgtgga gctgggttcc 180
atgcagggtga tgaacaagac ccggcgcatc atggagcagg gcgggacgca cttcatcaac 240
gccttcgtga ccacacccat gtgctgcccc tcacgctcct ccacccctac cggcaagtac 300
gtccacaacc acaacaccta caccaacaat gagaactgct cctcgccctc ctggcaggca 360
cagcacgaga gccgcacctt tgccgtgtac ctcaatagca ctggctaccg gacagctttc 420
ttcgggaagt atcttaatga atacaacggc tcctacgtgc caccggctg gaaggagtgg 480
gtcggactcc ttaaaaactc ccgcttttat aactacacgc tgtgtcggaa cggggtgaaa 540
gagaagcacg gctccgacta ctccaaggat tacctcacag acctcatcac caatgacagc 600
gtgagcttct tccgcacgtc caagaagatg taccgcaca ggccagtcct catggtcatc 660
agccatgcag cccccacgg ccctgaggat tcagccccac aatattcacg cctcttccca 720
aacgcatttc agcacatcac gccgagctac aactacgcgc ccaaccggga caaacttg 780
atcatgcgct acacggggcc catgaagccc atccacatgg aattcaccaa catgctccag 840
cggaagcgct tgcagaccct catgtcgggtg gacgactcca tggagacgat ttacaacatg 900
ctggttgaga cgggcgagct ggacaacacg tacatcgat acaccgccga ccacggttac 960
cacatcggcc agtttgccct ggtgaaagg aaatccatgc catatgagtt tgacatcagg 1020
gtcccgttct acgtgagggg cccaacgtg gaagccggct gtctgaatcc ccacatcgtc 1080
ctcaacattg acctggcccc caccatcctg gacattgcag gcctggacat acctgaggat 1140
atggacggga aatccatcct caagctgctg gacacggagc ggccggtgaa tcggtttcac 1200
ttgaaaaaga agatgagggg ctggcgggac tccttcttgg tggagagagg caagctgcta 1260
cacaagagag acaatgacaa ggtggacgcc caggaggaga actttctgcc caagtaccag 1320

cgtgtgaagg acctgtgtca gctgtgtgag taccagacgg cgtgtgagca gctgggacag 1380
 aagtggcagt gtgtggagga cgccacgggg aagctgaagc tgcataagt caagggcccc 1440
 atgcggctgg gcggcagcag agccctctcc aacctcgtgc ccaagtacta cgggcagggc 1500
 agcgaggcct gcacctgtga cagcggggac tacaagctca gcctggccgg acgccgaaa 1560
 aaactcttca agaagaagta caaggccagc tatgtccgca gtcgtccat ccgctcagt 1620
 gccatcgagg tggacggcag ggtgtaccac gtaggcctgg gtgatgccgc ccagccccga 1680
 aacctcacca agcggcactg gccagggggc cctgaggacc aagatgacaa ggatggtggg 1740
 gacttcagt gactggagg ccttcccgac tactcagccg ccaaccccat taaagtgaca 1800
 catcggtgct acatcctaga gaacgacaca gtccagtgtg acctggacct gtacaagtcc 1860
 ctgcaggcct ggaaagacca caagctgcac atcgaccacg agattgaaac cctgcagaac 1920
 aaaattaaga acctgaggga agtccgaggt cacctgaaga aaaagcggcc agaagaatgt 1980
 gactgtcaca aaatcagcta ccacaccag cacaaggcc gcctcaagca cagaggctcc 2040
 agtctgcac ctttcaggaa gggcctgcaa gagaaggaca aggtgtggct gttgcgggag 2100
 cagaagcgca agaagaaact ccgcaagctg ctcaagcgcc tgcagaacaa cgacacgtgc 2160
 agcatgccag gcctcacgtg cttcacccac gacaaccagc actggcagac ggcgcccttc 2220
 tggacactgg ggcccttctg tgcctgcacc agcgccaaca ataacacgta ctggtgcatg 2280
 aggaccatca atgagactca caatttcctc ttctgtgaat ttgcaactgg cttcctagag 2340
 tactttgatc tcaacacaga cccctaccag ctgatgaatg cagtgaacac actggacagg 2400
 gatgtcctca accagctaca cgtacagctc atggagctga ggagctgcaa gggttacaag 2460
 cagtgtacc cccggactcg aaacatggac ctgggactta aagatggagg aagctatgag 2520
 caatacaggc agtttcagcg tcgaaagtgg ccagaaatga agagaccttc ttccaaatca 2580
 ctgggacaac tgtgggaagg ctgggaaggt 2610

<210> 4

<400> 4

000

<210> 5

<400> 5

000

<210> 6

<400> 6

000

<210> 7

<400> 7

000

<210> 8

<400> 8

000

<210> 9
<400> 9
000

<210> 10
<400> 10
000

<210> 11
<211> 4397
<212> DNA
<213> Homo sapiens

<400> 11
gagcgagagt gtgtcgagt agtgtgcgtc tgtgtgtccc ggcgaggggtg cgcgctcggc 60
gccgggagcg cgccagccg agtccggagg catcgggagg tcgagagccg ccgggacccc 120
agctctgctg tactgcccc gtccggagct ggacttcggg gccggggccg gggccgtgcg 180
ccggggacag gcagggcccg gtccggggcc ggcgctccc caggccggag atctgcgagt 240
gaagagggac aagggaag aaacaaagcc acagacgcaa cttgagactc ccgcatccca 300
aaagaagcac cagatcagca aaaaaagaag atgggcccc cgagcctcgt gctgtgcttg 360
ctgtccgcaa ctgtgttctc cctgctgggt ggaagctcgg ccttctgtc gcaccaccgc 420
ctgaaaggca ggtttcagag ggaccgcagg aacatccgcc ccaacatcat cctgggtgctg 480
acggacgacc aggatgtgga gctgggttcc atgcaggtga tgaacaagac ccggcgcatc 540
atggagcagg gcgggacgca cttcatcaac gccttcgtga ccacacccat gtgctgcccc 600
tcacgtcct ccacctcac cggcaagtac gtccacaacc acaacaccta caccaacaat 660
gagaactgct cctcgccctc ctggcaggca cagcacgaga gccgcacctt tgccgtgtac 720
ctcaatagca ctggctaccg gacagctttc ttccgggaagt atcttaatga atacaacggc 780
tcctacgtgc caccggctg gaaggagtgg gtccgactcc ttaaaaaactc ccgcttttat 840
aactacacgc tgtgtcggaa cggggtgaaa gagaagcacg gctccgacta ctccaaggat 900
tacctcacag acctcatcac caatgacagc gtgagcttct tccgcacgtc caagaagatg 960
taccgcaca ggccagtct catggtcatc agccatgcag ccccccacgg cctgaggat 1020
tcagccccac aatattcacg cctcttccca aacgcattc agcacatcac gccgagctac 1080
aactacgcgc ccaacccgga caaacactgg atcatgcgct acacggggcc catgaagccc 1140
atccacatgg aattcaccaa catgctccag cggaagcgct tgcagaccct catgtcgggtg 1200
gacgactcca tggagacgat ttacaacatg ctggttgaga cgggcgagct ggacaacacg 1260
tacatcgat acaccgccg ccacggttac cacatcgcc agtttgccct ggtgaaagg 1320
aaatccatgc catatgagtt tgacatcagg gtcccgttct acgtgagggg ccccaacgtg 1380
gaagccggct gtctgaatcc ccacatcgtc ctcaacattg acctggcccc caccatcctg 1440
gacattgcag gcctggacat acctgcggat atggacggga aatccatcct caagctgctg 1500
gacacggagc ggccggtgaa tcggtttcac ttgaaaaaga agatgaggggt ctggcgggac 1560
tccttcttgg tggagagagg caagctgcta cacaagagag acaatgacaa ggtggacgcc 1620
caggaggaga actttctgcc caagtaccag cgtgtgaagg acctgtgtca gctgctgag 1680
taccagacgg cgtgtgagca gctgggacag aagtggcagt gtgtggagga gccacgggg 1740
aagctgaagc tgcataagt caaggcccc atgcggtgg gccgcagcag agccctctcc 1800
aacctcgtgc ccaagtacta cgggcagggc agcgaggcct gcacctgtga cagcggggac 1860

<213> Homo sapiens

<400> 12

Asp Ser Arg Ile Pro Lys Glu Ala Pro Asp Gln Gln Lys Lys Lys Met
1 5 10 15

Gly Pro Pro Ser Leu Val Leu Cys Leu Leu Ser Ala Thr Val Phe Ser
20 25 30

Leu Leu Gly Gly Ser Ser Ala Phe Leu Ser His His Arg Leu Lys Gly
35 40 45

Arg Phe Gln Arg Asp Arg Arg Asn Ile Arg Pro Asn Ile Ile Leu Val
50 55 60

Leu Thr Asp Asp Gln Asp Val Glu Leu Gly Ser Met Gln Val Met Asn
65 70 75 80

Lys Thr Arg Arg Ile Met Glu Gln Gly Gly Thr His Phe Ile Asn Ala
85 90 95

Phe Val Thr Thr Pro Met Cys Cys Pro Ser Arg Ser Ser Ile Leu Thr
100 105 110

Gly Lys Tyr Val His Asn His Asn Thr Tyr Thr Asn Asn Glu Asn Cys
115 120 125

Ser Ser Pro Ser Trp Gln Ala Gln His Glu Ser Arg Thr Phe Ala Val
130 135 140

Tyr Leu Asn Ser Thr Gly Tyr Arg Thr Ala Phe Phe Gly Lys Tyr Leu
145 150 155 160

Asn Glu Tyr Asn Gly Ser Tyr Val Pro Pro Gly Trp Lys Glu Trp Val
165 170 175

Gly Leu Leu Lys Asn Ser Arg Phe Tyr Asn Tyr Thr Leu Cys Arg Asn
180 185 190

Gly Val Lys Glu Lys His Gly Ser Asp Tyr Ser Lys Asp Tyr Leu Thr
195 200 205

Asp Leu Ile Thr Asn Asp Ser Val Ser Phe Phe Arg Thr Ser Lys Lys
210 215 220

Met Tyr Pro His Arg Pro Val Leu Met Val Ile Ser His Ala Ala Pro
225 230 235 240

His Gly Pro Glu Asp Ser Ala Pro Gln Tyr Ser Arg Leu Phe Pro Asn
245 250 255

Ala Ser Gln His Ile Thr Pro Ser Tyr Asn Tyr Ala Pro Asn Pro Asp
260 265 270

Lys His Trp Ile Met Arg Tyr Thr Gly Pro Met Lys Pro Ile His Met
275 280 285

Glu Phe Thr Asn Met Leu Gln Arg Lys Arg Leu Gln Thr Leu Met Ser
290 295 300

Val Asp Asp Ser Met Glu Thr Ile Tyr Asn Met Leu Val Glu Thr Gly
305 310 315 320

Glu Leu Asp Asn Thr Tyr Ile Val Tyr Thr Ala Asp His Gly Tyr His
325 330 335

Ile Gly Gln Phe Gly Leu Val Lys Gly Lys Ser Met Pro Tyr Glu Phe
340 345 350

Asp Ile Arg Val Pro Phe Tyr Val Arg Gly Pro Asn Val Glu Ala Gly
355 360 365

Cys Leu Asn Pro His Ile Val Leu Asn Ile Asp Leu Ala Pro Thr Ile
370 375 380

Leu Asp Ile Ala Gly Leu Asp Ile Pro Ala Asp Met Asp Gly Lys Ser
385 390 395 400

Ile Leu Lys Leu Leu Asp Thr Glu Arg Pro Val Asn Arg Phe His Leu
405 410 415

Lys Lys Lys Met Arg Val Trp Arg Asp Ser Phe Leu Val Glu Arg Gly
420 425 430

Lys Leu Leu His Lys Arg Asp Asn Asp Lys Val Asp Ala Gln Glu Glu
435 440 445

Asn Phe Leu Pro Lys Tyr Gln Arg Val Lys Asp Leu Cys Gln Arg Ala
450 455 460

Glu Tyr Gln Thr Ala Cys Glu Gln Leu Gly Gln Lys Trp Gln Cys Val
465 470 475 480

Glu Asp Ala Thr Gly Lys Leu Lys Leu His Lys Cys Lys Gly Pro Met
485 490 495

Arg Leu Gly Gly Ser Arg Ala Leu Ser Asn Leu Val Pro Lys Tyr Tyr
500 505 510

Gly Gln Gly Ser Glu Ala Cys Thr Cys Asp Ser Gly Asp Tyr Lys Leu
515 520 525

Ser Leu Ala Gly Arg Arg Lys Lys Leu Phe Lys Lys Lys Tyr Lys Ala
530 535 540

Ser Tyr Val Arg Ser Arg Ser Ile Arg Ser Val Ala Ile Glu Val Asp
545 550 555 560

Gly Arg Val Tyr His Val Gly Leu Gly Asp Ala Ala Gln Pro Arg Asn
565 570 575

Leu Thr Lys Arg His Trp Pro Gly Ala Pro Glu Asp Gln Asp Asp Lys
580 585 590

Asp Gly Gly Asp Phe Ser Gly Thr Gly Gly Leu Pro Asp Tyr Ser Ala
595 600 605

Ala Asn Pro Ile Lys Val Thr His Arg Cys Tyr Ile Leu Glu Asn Asp
610 615 620

Thr Val Gln Cys Asp Leu Asp Leu Tyr Lys Ser Leu Gln Ala Trp Lys
625 630 635 640

Asp His Lys Leu His Ile Asp His Glu Ile Glu Thr Leu Gln Asn Lys
645 650 655

Ile Lys Asn Leu Arg Glu Val Arg Gly His Leu Lys Lys Lys Arg Pro
660 665 670

Glu Glu Cys Asp Cys His Lys Ile Ser Tyr His Thr Gln His Lys Gly
675 680 685

Arg Leu Lys His Arg Gly Ser Ser Leu His Pro Phe Arg Lys Gly Leu
690 695 700

Gln Glu Lys Asp Lys Val Trp Leu Leu Arg Glu Gln Lys Arg Lys Lys
705 710 715 720

Lys Leu Arg Lys Leu Leu Lys Arg Leu Gln Asn Asn Asp Thr Cys Ser
725 730 735

Met Pro Gly Leu Thr Cys Phe Thr His Asp Asn Gln His Trp Gln Thr
740 745 750

Asn Asn Thr Tyr Trp Cys Met Arg Thr Ile Asn Glu Thr His Asn Phe
770 775 780

785
Thr Asp Pro Tyr Gln Leu Met Asn Ala Val Asn Thr Leu Asp Arg Asp
805 810 815

Gly Tyr Lys Gln Cys Asn Pro Arg Thr Arg Asn Met Asp Leu Gly Leu
835 840 845

Trp Pro Glu Met Lys Arg Pro Ser Ser Lys Ser Leu Gly Gln Leu Trp
865 870 875 880

Glu Gly Trp Glu Gly
885